RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
CASI, a US in-licensing pharma with operations in China, acquired global rights to an investigational anti-CD38 immunotherapy from Black Belt Therapeutics of the UK. CASI made a $5.5 million upfront payment and invested $2.2 million in Black Belt. It will also be responsible for milestone and royalty payments. Black Belt was spun out of Tusk when it was acquired by Roche last year. The candidate, TSK011010, is ready to submit an IND, with Phase I trials expected to start in late 2019 or early 2020.
Source: China Biotoday
